project: cardiodx

CardioDX logo

Connect with a Sales Specialist

x

CardioDx Board of Directors

Patrick G. Enright | Managing Director, Longitude Capital

Mr. Enright has served as a member of our board of directors since February 2011. Since 2006, Mr. Enright has served as a Managing Director of Longitude Capital, a venture capital firm, of which he is a founder. From 2002 through 2006, Mr. Enright was a Managing Director of Pequot Ventures, a venture capital firm, where he co-led the life sciences investment practice. Mr. Enright also has significant life sciences operations experience, beginning his career more than 25 years ago at Sandoz (now Novartis AG). He currently serves on the boards of directors of Jazz Pharmaceuticals plc, Corcept Therapeutics Incorporated, Esperion Therapeutics, Inc., and several privately-held companies. In the past five years he also served as a director of Threshold Pharmaceuticals, Inc. and Sequenom, Inc. Mr. Enright received an M.B.A. from the Wharton School at the University of Pennsylvania and a B.S. in Biological Sciences from Stanford University. 

Andrew Guggenhime | Chief Operating Officer & Chief Financial Officer, Dermira

Andrew Guggenhime joined CardioDx in September 2011 as Chief Financial Officer and has served as a member of our board of directors since April 2014. Andrew has more than 12 years of CFO experience, of which, more than nine years were serving public companies. From September 2010 to April 2011, he served as CFO of Calistoga Pharmaceuticals, Inc., a privately-held biotechnology company acquired in April 2011 by Gilead Sciences. Prior to Calistoga Pharmaceuticals, Andrew served as Senior Vice President and Chief Financial Officer for Facet Biotech Corporation, a publicly-held company acquired in April 2010 by Abbott Laboratories. He also served as CFO for PDL BioPharma, Inc., a publicly-held biopharmaceutical company, and Neoforma, Inc., a provider of supply-chain management solutions for the healthcare industry. Andrew began his career in financial services at Merrill Lynch & Co. and Wells Fargo & Company. He holds an M.B.A. from the J.L. Kellogg Graduate School of Management at Northwestern University and a B.A. in International Politics and Economics from Middlebury College.

Hongjie Hu | Director, Investments, Temasek

Louis G. Lange, M.D., Ph.D. | Partner, Asset Management Company

Dr. Lange is currently Chairman of the Board and has served as a member of our board of directors since September 2009. Dr. Lange is currently a partner with Asset Management Company, a venture capital firm that he joined in June 2009. Dr. Lange founded CV Therapeutics, Inc., a biotechnology company, in 1992, where he served as Chairman, Chief Executive Officer and Chief Scientific Officer, overseeing the successful commercialization of a product portfolio solely focused on cardiovascular health through its sale to Gilead Sciences in 2009. Dr. Lange has over 20 years’ experience in academic medicine at Harvard University and Washington University, where he served as Chief of Cardiology and Professor of Medicine at Jewish Hospital from 1985 to 1992 and was one of the first academicians in molecular cardiology. Dr. Lange currently sits on the board of directors of Maxygen, Inc., Esperion Therapeutics, Inc. and multiple private companies. Dr. Lange holds an M.D. from Harvard Medical School and a Ph.D. in Biochemistry from Harvard University and received an A.B. in Chemistry from University of Rochester.

Khush F. Mehta | President and CEO, CardioDx

Ajit Singh, Ph.D. | Managing Director, Artiman Management, LLC

Dr. Singh has served as a member of our board of directors since April 2012. Since January 2011, Dr. Singh has been a managing director of Artiman Management, L.L.C., a venture capital firm, where he focuses on investing in early-stage technology, life sciences and medical technology companies. Prior to joining Artiman, he was the President and Chief Executive Officer of BioImagene, Inc., a digital pathology company, from October 2008 until BioImagene was acquired by Ventana Medical Systems, Inc., a member of the Roche Group, in September 2010. Dr. Singh also serves on the boards of several privately-held companies and Max India Ltd, which is listed on stock exchanges in India. Dr. Singh is also a Consulting Professor in the School of Medicine at Stanford University. Dr. Singh holds a Ph.D. in Computer Science from Columbia University, an M.S. in Computer Engineering from Syracuse University and a B.S. in Electrical Engineering from Banaras Hindu University, India. 

James R. Tobin | Former CEO, Boston Scientific Corporation

James R. Tobin has served as a member of our board of directors since April 2014. Mr. Tobin has over 40 years of healthcare industry experience. From 1999 to 2009, he served as Chief Executive Officer and President of Boston Scientific Corporation, a medical device company. Prior to Boston Scientific, he was President of Biogen, Inc. (now Biogen Idec) and Baxter International, Inc. Currently, he serves on the Board of Directors of Curis, Inc., and several other private companies. Mr. Tobin received his M.B.A. from Harvard Business School and a B.A. from Harvard College.